Oxford Immunotec Appoints Stefan Linn as Chief Operating Officer
(Thomson Reuters ONE) -
OXFORD, United Kingdom and MARLBOROUGH, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) --
Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics
company focused on developing and commercializing proprietary tests for the
management of underserved immune-regulated conditions, today announced the
appointment of Stefan Linn as Chief Operating Officer.
Mr. Linn joins Oxford Immunotec with extensive experience building and leading
companies through growth strategies, operational improvements, and acquisitions.
Most recently, Mr. Linn served as Senior Vice President, Strategy and Commercial
Operations, for IMS Health Holdings, Inc. In this role, he was responsible for
advancing IMS Health's global growth agenda, including leading strategic
planning and commercial operations activities, expansion of the company's
product offering, and the identification and integration of acquisitions.
"We are delighted to welcome Stefan to the Oxford Immunotec team and to announce
this additional progress in strengthening our management team," said CEO, Dr.
Peter Wrighton-Smith. "Stefan's decades of broad operational and commercial
experience will be very beneficial as we advance the Company through the next
phase of rapid growth."
Mr. Linn joined IMS Health from TPG Capital, where he worked with TPG's
healthcare and consumer portfolio companies to drive operating improvements.
Prior to joining TPG, Mr. Linn was a Senior Vice President at McKesson
Corporation, where he was responsible for marketing strategy, product
development and customer programs. During his tenure at McKesson, Mr. Linn also
served as President of Health Mart, and oversaw McKesson's consumer products
division, packaging business RxPack, and the McKesson Patient Relationship
Solutions division. Earlier in his career, Mr. Linn was a Vice President at
Merck-Medco Managed Care, LLC, and also worked for McKinsey & Company. He holds
a B.A. in Economics from the University of Dallas and an M.B.A. from the
University of California at Berkeley.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused
on developing and commercializing proprietary tests for the management of
underserved immune-regulated conditions. The Company's first product is the T-
SPOT®.TB test, which is used to test for tuberculosis infection. The T-
SPOT.TB test has been approved for sale in over 50 countries, including the
United States, where it has received pre-market approval from the Food and Drug
Administration, Europe, where it has obtained a CE mark, as well as Japan and
China. The Company's second product line is a range of assays for tick-borne
diseases, such as Lyme disease, obtained through the acquisitions of Imugen and
Immunetics. Also obtained through the acquisitions is the Company's third
product line focused on screening for Babesia in donated blood, for which the
Company is currently seeking FDA licensure. The T-SPOT.CMV test and the T-
SPOT.PRT test are pipeline products as part of the Company's fourth intended
product line focused on the transplantation market. In addition to these four
product lines, the Company has additional active development programs in other
immune-regulated conditions. The Company is headquartered near Oxford, U.K. and
in Marlborough, Mass. Additional information can be found
at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.
Immunetics is a trademark of Immunetics, Inc.
CONTACT:
For Media and Investor Inquiries:
Karen Koski
Head of Strategy and Investor Relations
Oxford Immunotec
Tel: +1 (508) 556-1377
kkoski(at)oxfordimmunotec.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Oxford Immunotec via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 30.08.2017 - 15:00 Uhr
Sprache: Deutsch
News-ID 558298
Anzahl Zeichen: 4493
contact information:
Town:
Oxfordshire
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 503 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Oxford Immunotec Appoints Stefan Linn as Chief Operating Officer"
steht unter der journalistisch-redaktionellen Verantwortung von
Oxford Immunotec (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
